Johnson & Johnson's Revenue and Earnings Slipped in the Second Quarter

It wasn't a pretty second quarter for Johnson & Johnson (NYSE:JNJ), but the issues caused by the coronavirus pandemic were expected. In fact, the sales and earnings declines weren't as bad the healthcare conglomerate was expecting, which led management to raise its 2020 guidance.